Precision BioSciences, Inc. (DTIL)

NASDAQ: DTIL · IEX Real-Time Price · USD
18.32
+2.28 (14.21%)
Feb 28, 2024, 2:54 PM EST - Market open
14.21%
Market Cap 65.02M
Revenue (ttm) 52.29M
Net Income (ttm) -73.52M
Shares Out 4.06M
EPS (ttm) -18.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,120
Open 15.87
Previous Close 16.04
Day's Range 15.63 - 18.50
52-Week Range 8.25 - 36.15
Beta 1.40
Analysts Strong Buy
Price Target 61.00 (+232.97%)
Earnings Date Mar 7, 2024

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treat... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2019
Employees 115
Stock Exchange NASDAQ
Ticker Symbol DTIL
Full Company Profile

Financial Performance

In 2022, DTIL's revenue was $25.10 million, a decrease of -78.28% compared to the previous year's $115.53 million. Losses were -$111.64 million, 264.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price forecast is $61.0, which is an increase of 232.97% from the latest price.

Price Target
$61.0
(232.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

8 days ago - Business Wire

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

14 days ago - Business Wire

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

15 days ago - Business Wire

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

Other symbols: TGTX
16 days ago - Business Wire

Precision BioSciences to Effect a Reverse Stock Split

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

19 days ago - Business Wire

TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

TG Therapeutics Inc.'s stock TGTX, -1.36% rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. DTIL, +10.10% to acquire a worldwide l...

Other symbols: TGTX
7 weeks ago - Market Watch

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

Other symbols: TGTX
7 weeks ago - Business Wire

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

2 months ago - Business Wire

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences to Present at Hep-DART 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD's The Liver Meeting 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences to Present at Upcoming Sidoti Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

3 months ago - Business Wire

Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

4 months ago - Business Wire

Precision BioSciences to Report Third Quarter Results on November 7, 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

4 months ago - Business Wire

Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

4 months ago - Business Wire

Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for...

4 months ago - Business Wire

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

4 months ago - Business Wire

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo...

5 months ago - Business Wire

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, t...

6 months ago - Business Wire

Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced t...

6 months ago - Business Wire

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo ...

6 months ago - Business Wire

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion of a...

7 months ago - Business Wire

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, to...

7 months ago - Business Wire